Study identifier:CD-RI-MEDI2338-1033
ClinicalTrials.gov identifier:N/A
EudraCT identifier:2010-022879-54
CTIS identifier:N/A
A Phase 1, Single Ascending Dose Study to Evaluate the Safety of MEDI2338 in Subjects with Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Phase 1
No
-
All
31
Interventional
40 Years - 99 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Single Blind
Primary Purpose: Treatment
Verified 01 Oct 2013 by MedImmune, LLC
MedImmune, LLC
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: MEDI2338 10 MG MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump | Biological/Vaccine: MEDI2338 MEDI2338 single intravenous (IV) dose (lowest dose) |
Experimental: MEDI2338 30 MG MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump | Biological/Vaccine: MEDI2338 MEDI2338 single IV dose (next highest dose) |
Experimental: MEDI2338 100 MG MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump | Biological/Vaccine: MEDI2338 MEDI2338 single IV dose (next highest dose) |
Experimental: MEDI2338 300 MG MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump | Biological/Vaccine: MEDI2338 MEDI2338 single IV dose (next highest dose) |
Experimental: MEDI2338 1000 MG MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump | Biological/Vaccine: MEDI2338 MEDI2338 single IV dose (highest dose) |
Placebo Comparator: Placebo Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump | Other: Placebo Placebo single IV dose |